Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This study is an extension of a study that has been ongoing for 1 year. The purpose of this
open label study is to see the how well type 2 diabetics respond to
VI-0521(phentermine/topiramate) in controlling blood sugar and how safe VI-0521 is over an
extended period of time. All subjects eligible to enroll into this study will receive study
drug.